Pancreatic Cancer - Epidemiology Forecast - 2032

This ‘Pancreatic Cancer - Epidemiology Forecast-2032' report delivers an in-depth understanding of the pancreatic cancer historical and forecasted epidemiology as well as the pancreatic cancer epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Pancreatic Cancer Understanding

Pancreatic Cancer Overview

Pancreatic cancer begins in the tissues of the pancreas - an organ in the abdomen that lies behind the lower part of the stomach. The pancreas release enzymes that aid digestion and produces hormones that help manage blood sugar. Pancreatic cancer is a disease in which malignant (cancer) cells form in the tissues of the pancreas. Several types of growth can occur in the pancreas, including cancerous and noncancerous tumors. The most common type of cancer that forms in the pancreas begins in the cells that line the ducts that carry digestive enzymes out of the pancreas (pancreatic ductal adenocarcinoma). Pancreatic cancer is seldom detected at its early stages when it is most curable, and this is because it often does not cause symptoms until after it has spread to other organs. Pancreatic cancer treatment options are chosen based on the extent of the cancer. Options may include surgery, chemotherapy, radiation therapy, or a combination of these.

Pancreatic cancer occurs when cells in the pancreas develop changes (mutations) in their DNA. A cell's DNA contains the instructions that tell a cell what to do. These mutations tell the cells to grow uncontrollably and to continue living after normal cells would die. These accumulating cells can form a tumor. When left untreated, pancreatic cancer cells can spread to nearby organs, blood vessels, and distant body parts.

Pancreatic Cancer Diagnosis

Pancreatic cancer is difficult to diagnose because the symptoms of pancreatic cancer are often mistaken for those of other illnesses, such as irritable bowel syndrome. It may go undetected until it's advanced. By the time symptoms occur, diagnosing pancreatic cancer is usually relatively straightforward; unfortunately, a cure is rarely possible. Diagnosing pancreatic cancer usually happens when someone comes to the doctor after experiencing weeks or months of symptoms. Pancreatic cancer symptoms frequently include abdominal pain, weight loss, itching, or jaundice (yellow skin). It is crucially important that patients are diagnosed as early as possible because early diagnosis can increase the chance of a patient having surgery to remove the tumor - currently the only potential cure. At present, only around 10% of cases are eligible for resectional surgery.

Multiple biomarkers based on mutation panels, antibodies, circulating DNA, microRNAs, proteins, metabolites, methylated DNA, and exosomes have been tested for pancreatic cancer screening; however, they suffer from a lack of application in longitudinal screening of asymptomatic individuals and are still not ready for clinical use, except for one. Carbohydrate antigen 19-9 (CA 19-9) is the only tumor marker approved by the US Food and Drug Administration (FDA) and used for treatment monitoring in pancreatic cancer.

Pancreatic Cancer Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Pancreatic Cancer, Molecular Alteration-specific Incident Cases of Pancreatic Cancer, and Stage-specific Incident Cases of Pancreatic Cancer scenario in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Pancreatic Cancer Detailed Epidemiology Segmentation

• In 2021, the total incident cases of pancreatic cancer in the 7MM countries were 175,767 cases, and these cases are anticipated to increase during the study period.
• Among the European countries, Germany had the highest incident cases of pancreatic cancer in 2021, i.e., 21,859 cases, followed by France which had 14,989 incident cases in 2021. On the other hand, Spain had the lowest incident cases of pancreatic cancer, i.e. 8,566 cases in 2021. Japan had 43,170 incident cases of pancreatic cancer in 2021.
• In terms of stage-specific incident cases, maximum number of patients were observed for distant pancreatic cancer. This was followed by regional and localized pancreatic cancer.
• According to the publisher, majority of pancreatic cancer cases are caused by KRAS2 mutation followed by TP53 and SMAD4/DPC4 mutations. Least number of incident cases were observed for pancreatic cancer associated with NTRK mutation.

Scope of the Report

• The report covers the descriptive overview of pancreatic cancer, explaining its causes, signs, and symptoms, pathophysiology, and diagnosis.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden.
• The report provides the segmentation of the disease epidemiology for 7MM by segmented by ‘Total Incident Cases of Pancreatic Cancer, Molecular Alteration-specific Incident Cases of Pancreatic Cancer, and Stage-specific Incident Cases of Pancreatic Cancer.'

Report Highlights

• 11-Year Forecast of pancreatic cancer
• 7MM Coverage
• Total Incident Cases of pancreatic cancer
• Molecular Alteration-specific Incident Cases of pancreatic cancer
• Stage-specific Incident Cases of pancreatic cancer

Key Questions Answered

• What are the disease risk, burdens, and unmet needs of pancreatic cancer?
• What is the historical pancreatic cancer patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of pancreatic cancer at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to pancreatic cancer?
• Out of the countries mentioned above, which country would have the highest patient population of pancreatic cancer during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to Buy

The pancreatic cancer report will allow the user to -

• Develop business strategies by understanding the trends, shaping and driving the 7MM pancreatic cancer epidemiology.
• The pancreatic cancer epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The pancreatic cancer epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032